Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022.

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021.

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

Company begins 2022 with multiple active programs with data readouts expected this year

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19

Vaxart's S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline

Pharmaceutical Industry Veteran Brings Broad Legal Expertise  to Vaxart Senior Management Team

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

This vaccine company has a lot of catching up to do.

Is Vaxart Stock a Buy Now?

VAXART, INC. (VXRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy

Does Vaxart's Oral COVID Vaccine Have a Chance?

Bionano Genomics

Intercept Pharma

Ocugen, Inc.

Select analysts and investment banks believe these little-known companies can skyrocket.

4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street

Could Vaxart's Vaccine Pill Help to End the Pandemic?

Marathon Digital Holdings

Nikola

Novavax

This diverse mix of companies is expected to deliver revenue growth of 236% to 5,460% this year.

4 of the Fastest-Growing Stocks on the Planet in 2022

This biotechnology company has a nifty trick up its sleeve.

Is This Vaccine Stock a Buy?

VXRT stock is more than a Covid-19 meme trade. But is there enough fundamentals there to support an investment heading into 2022?

Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger

As the Covid-19 vaccine maker expands into a second manufacturing facility, VXRT stock remains an undervalued gem. The post Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine appeared first on InvestorPlace.

Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine

Catalyst Pharmaceuticals

They've strongly outperformed the market in the past, and they could easily do it again.

2 Top Healthcare Stocks Ready for a Bull Run in 2022

Vaxart Inc. (NASDAQ:VXRT) shares were trading higher Friday after the company plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant in two studies expected to begin next month. The stock has climbed back above a key level that was holding as support for a time.

Vaxart Stock Crosses 2 Key Levels Friday: What's Next?

Vaxart Inc (NASDAQ: VXRT) plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant in two different studies expected to begin next month. Vaxart will test its COVID-19 oral vaccine candidate against omicron in the first study.

Vaxart to Test Cross-Reactivity of its COVID-19 Oral Vaccine Against Omicron

Redfin

Zoom Video

Select analysts and investment banks see these fast-paced stocks soaring next year.

4 Growth Stocks With 119% to 189% Upside in 2022, According to Wall Street

Vaxart is the oral vaccine developer with COVID, RSV, HPV, influenza and Norovirus candidates in its pipeline.

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Pfizer

The initial data on omicron suggests that the pandemic has entered a new, less deadly phase.

Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today

Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart. The post VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down appeared first on InvestorPlace.

VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down

Purchase expected to give Vaxart greater control over manufacturing schedules Purchase expected to give Vaxart greater control over manufacturing schedules

Vaxart Announces Acquisition of Second GMP Manufacturing Facility

Vaxart Inc. (NASDAQ:VXRT) shares were trading higher Monday. A company executive will present an overview of the company's COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Congress on Tuesday, Nov. 30.

Vaxart Stock Breaks Out Of Pennant Pattern: Now What?

Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Wednesday.  The company announced that an executive will present an overview of the company's COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Congress on Tuesday, Nov. 30, 2021.

News for Vaxart Stock (VXRT)